<DOC>
	<DOC>NCT02115581</DOC>
	<brief_summary>This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.</brief_summary>
	<brief_title>Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy</brief_title>
	<detailed_description>This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy. In a prospective, randomized, double-blinded, placebo-controlled trial, patients younger than 18 years with idiopathic dilated cardiomyopathy randomizes to receive either Coenzyme Q10 or placebo. Echocardiographic systolic and diastolic function parameters are determined for every patient at baseline, after three,six and nine months of supplementation.</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy, Dilated</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Known cases of Idiopathic Dilated Cardiomyopathy (IDC) Those patients in whom heart failure medications were stable for at least 1 month More than 6 months aged Recent modification in medications Hemodynamic instability Congenital heart disease Metabolic heart disease Cardiac dysfunction resulting from abnormalities in other organs and those with an acquired cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Coenzyme O10</keyword>
	<keyword>Children</keyword>
	<keyword>Idiopathic Dilated Cardiomyopathy</keyword>
</DOC>